|
Real-time
Boerse Muenchen
10:00:02 15/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 106.96 EUR | +1.56% |
|
-4.93% | +4.23% |
| 04:40am | Paradigm Biopharmaceuticals Names Chief Medical Officer | MT |
| 09-14 | ASX Midday Sector Update: Healthcare Stocks Advance, Materials Sector Struggles | MT |
| Market Cap | 58.62B 50.79B 47.93B 43.49B 81.58B 5,618B 82.17B 572B 221B 2,850B 220B 215B 9,061B | P/E 2027 * |
20.1x | P/E 2028 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 67.55B 58.53B 55.24B 50.11B 94B 6,474B 94.68B 660B 254B 3,284B 254B 248B 10,442B | EV / Sales 2027 * |
4.29x | EV / Sales 2028 * | 4.11x |
| Free-Float |
99.97% | Yield 2027 * |
2.45% | Yield 2028 * | 2.6% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CSL | Delayed | |
OTC Markets
| CMXHF | Delayed | |
|
Börse Stuttgart
| CSJ | Delayed | |
|
Berne S.E.
| CSJ | End-of-day quote | |
|
Boerse Muenchen
| CSJ | Real-time | |
|
Tradegate
| CSJ | Real-time | |
|
Deutsche Boerse AG
| CSJ | Delayed |
Last Transcript: CSL Limited
| 1 week | +0.40% | ||
| Current month | +0.69% | ||
| 1 month | +26.89% | ||
| 3 months | +59.58% | ||
| 6 months | +21.49% | ||
| Current year | +6.20% |
| 1 week | 101.6 |  | 108.96 |
| 1 month | 83 | | 108.96 |
| 3 years | 56 | | 192.12 |
| 5 years | 56 | | 205.95 |
| 10 years | 56 | | 212.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gordon Naylor
CEO | Chief Executive Officer | 63 | 11/02/2026 |
Ken Lim
DFI | Director of Finance/CFO | 52 | 07/10/2025 |
Mary Oates
COO | Chief Operating Officer | - | 01/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 17/10/2018 | |
Brian McNamee
BRD | Director/Board Member | 70 | 02/02/2011 |
Carolyn Hewson
BRD | Director/Board Member | 71 | 09/12/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.56% | -4.93% | -10.96% | -34.73% | 58.62B | |
| +1.57% | -4.11% | +41.74% | -4.64% | 79.26B | |
| +1.89% | +0.78% | +523.95% | +30.03% | 58.56B | |
| +1.57% | -0.31% | -14.78% | -34.90% | 58.62B | |
| +0.35% | -3.14% | -11.03% | +26.34% | 48.75B | |
| +2.38% | +0.10% | +1.49% | +155.34% | 46.32B | |
| +0.10% | -1.57% | +50.05% | -15.20% | 32.12B | |
| +0.59% | -3.60% | +47.04% | +92.49% | 24.77B | |
| -1.70% | -4.99% | -0.42% | +142.86% | 21.5B | |
| +2.24% | -0.40% | +66.12% | +100.09% | 15.97B | |
| Average | +0.79% | -1.72% | +69.32% | +45.77% | 42.87B | |
| Weighted average by Cap. | +0.93% | -1.65% | +80.62% | +27.58% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 15.76B 13.66B 12.89B 11.69B 21.93B 1,511B 22.09B 154B 59.32B 766B 59.2B 57.9B 2,436B | 16.31B 14.13B 13.34B 12.1B 22.7B 1,563B 22.86B 159B 61.38B 793B 61.26B 59.91B 2,521B |
| Net income | 2.84B 2.46B 2.32B 2.1B 3.95B 272B 3.98B 27.71B 10.68B 138B 10.66B 10.42B 439B | 3.17B 2.74B 2.59B 2.35B 4.41B 303B 4.44B 30.92B 11.91B 154B 11.89B 11.63B 489B |
| Net Debt | 8.93B 7.74B 7.3B 6.63B 12.43B 856B 12.52B 87.22B 33.61B 434B 33.54B 32.8B 1,380B | 8.46B 7.33B 6.92B 6.28B 11.78B 811B 11.86B 82.65B 31.85B 411B 31.78B 31.08B 1,308B |
| Date | Price | Change |
|---|---|---|
| 15/09/26 | €106.96 | +1.56% |
| 14/09/26 | €105.32 | +1.90% |
| 11/09/26 | €103.36 | +0.10% |
| 10/09/26 | €103.26 | -1.79% |
| 09/09/26 | €105.14 | -2.65% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CSL Stock
- CSJ Stock
Select your edition
All financial news and data tailored to specific country editions
